Company news

Aldeyra Therapeutics, Inc. news in 2019

Aldeyra Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy

December 18, 2019

Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

December 2, 2019

Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

December 1, 2019

Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

November 6, 2019

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update

October 31, 2019

Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

October 30, 2019

Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

October 29, 2019

Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting

September 25, 2019

Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy

September 23, 2019

Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 8, 2019

Decks in 2019